Physician profile
Charles A Evans
NPI 1255334538
$3,389.77
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $641 · 2021: $896 · 2022: $475 · 2023: $427 · 2024: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.65 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $439.84 | 2019-2023 | Mounjaro |
| Abbvie INC. | $398.01 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.29 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.63 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $218.21 | 2019-2024 | Breztri |
| Merck Sharp & Dohme LLC | $204.70 | 2019-2021 | |
| Amgen INC. | $173.49 | 2019-2021 | |
| Pfizer INC. | $168.67 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $84.43 | 2019-2024 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $77.15 | 2019-2024 | Trintellix |
| Abbott Laboratories | $60.08 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Kaleo, INC. | $51.38 | 2020 | |
| Genentech USA, INC. | $38.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $36.46 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.94 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $35.79 | 2021-2022 | |
| Horizon Therapeutics Plc | $32.08 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.03 | 2023 | Keveyis |
| Biohaven Pharmaceuticals, INC. | $22.11 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.35 | 2021 | |
| Nevro Corp. | $14.35 | 2023 | Senza |
| Currax Pharmaceuticals LLC | $14.16 | 2023 | Contrave |
| Allergan, INC. | $13.28 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.64 | 2021 | |
| Eisai INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.